Table 1.
Main material | Scaffold format | PPy incorporation | Dopant/oxidant | Concentration | Electrical properties | Cell sources and usages | In vitro/vivo results | Ref. |
---|---|---|---|---|---|---|---|---|
ALG | Crosslinked hydrogel | Immerse coating | N.A./FeCl3 | [py]: 0–20 × 10−3 M | py[10]/ALG: 1.1 ± 0.3 × 10−4 S/cm | In vivo model/NTE | PPy/ALG hydrogels enhanced expression of Tuj1 and MAP2. | 43 |
Mild inflammatory reactions after 8 weeks of implantation. | ||||||||
ALG/COL | Crosslinked hydrogel | Mix ALG/COL with doped PPy | HCl/FeCl3 | ALG-graft-PPy: ALG (wt%): 20:80, 30:70 | 20%: 220 mS/cm | hMSCs/biocompatibility | No cytotoxicity effects. | 9 |
30%: 229 mS/cm | ||||||||
ALG/CHI | Crosslinked hydrogel | Mix ALG/CHI with doped PPy | HCl/APS | PPy: 0.02–0.4 g | 7.35 × 10−6–8.03 × 10−3 S/cm | PC12, RSC96, BMMSC/NTE | SA/CMCS/PPy hydrogels supported cell growth and proliferation. | 39 |
No severe inflammatory tissue responses when implanted in vivo. | ||||||||
Better nerve fibers morphology in SA/CMCS/PPy hydrogels than the autologous nerve group. | ||||||||
ALG/CHI | Doubled lyophilized foam | Mix ALG/CHI with py, then polymerize | HCl/FeCl3 | [py]: 0.1 M | 550–1000 nA | MG-63/BTE | CHI/PPy/ALG scaffold promoted the formation of apatite layer. | 44 |
CHI | Crosslinked hydrogel | Mix CHI with py, then polymerize | N.A./FeCl3 | [PPy]: 0.04% | N.A. | NRCM/CTE | Synchronous contraction of two distinct clusters of CMs connected by PPy/CHI composite. | 37 |
Higher EMG signal amplitude in scar tissue from PPy/CHI-treated animals. | ||||||||
CHI | Crosslinked gelfoam | Mix CHI with py, then polymerize | N.A./FeCl3 | N.A. | 12.5 × 10−5 S/cm | NRCM/CTE | Higher calcium transient velocity of CMs on PPy composite. | 38 |
Faster conduction velocity on the epicardial surface of PPy composite-implanted hearts. | ||||||||
COL | IPC-mesh | Immerse coating | Cl−/FeCl3 | N.A. | N.A. | hMSC/NTE | Upregulated expression of noggin, MAP2, neurofilament, β tubulin III, and nestin from hMSCs on PPy/COL scaffolds. | 62 |
COL | Hybrid microfibers hydrogel | Mix synthesized PPy with COL | N.A./FeCl3 | [PPy]: 0–1 mg/mL | Col 0.5: 0.22 S/m | PC12/NTE | Enhanced electroconductivity in PPy/COL hydrogel microfibers. | 63 |
[COL]: 6 mg/mL | ||||||||
Improved PC12 cells neurogenesis. | ||||||||
COL/PAR | Inkjet-printed scaffold | Print on top of PPy lines | PVA/FeCl3, FepTS | py: 136 mg | 1.1 S/cm | PC12/NTE | Promoted neurite outgrowth and orientation on PPy/COL scaffold with electrical stimulation. | 70 |
GX | Hydrogel | Electrochemically polymerization | GX/N.A. | [Py]: 0.4 M | Voltammetric peak: 0.2 (ox), −0.3 V (red) | Human fibroblast | Better cell adhesion on PPy/GX scaffold. | 61 |
External magnetic field helped cell adhesion and proliferation. | ||||||||
SF | Lyophilized foam | Immerse coating | HCl/APS | [py]: 14.28 mM | N.A. | hMSC/BTE | Increased collagen production of the hMSCs on PPy/SF scaffolds. | 49 |
SF | Acid modified film | Immerse coating | p-TSA/FeCl3 | [py]: 50 mM | 200–500 Ω/sq | hESC-derived CMs/CTE | Anisotropic topographical cues led to increased cellular organization and sarcomere development. | 52 |
Electroconductive cues promoted CX43 expression and polarization. | ||||||||
SF | 3D print and electrospinning composite | Immerse coating | HCl/FeCl3 | [py]: 14 mM | 1 × 10−5–1 × 10−3 S/cm | Mouse fibroblasts, SCs/NTE | No cytotoxicity and did not affect SC proliferation. | 1 |
SF | Electrospun mat | Immerse coating | NaCl/FeCl3 | [py]: 0.3 M | Similar voltammograms to free-standing PPy | hMSC, hfibroblasts/Biocompatibility | No cytotoxicity and supported cell proliferation in vitro. | 50 |
HA | Hydrogel | Immerse coating | N.A./APS | [py]: 0–100 Mm | 10−3–10−2 S/cm | 3T3/Biocompatibility | PPy/HA composites supported cell attachment and proliferation. | 59 |
HA/GEL | Self-adhesive hydrogel | Paint dopa-PPy on dopa-Gel/HA | N.A./FeCl3 | [dopa-PPy]: 0–0.6% | 1.09 ± 0.06 × 10−6–2.85 ± 0.18 × 10−4 S/cm | In vivo model/CTE | Dopa-Gel/PPy hydrogel could tightly adhere to the porcine myocardium. | 60 |
[dopa-Gel]: 25% | ||||||||
Smaller infarct sizes and thicker left ventricle walls. | ||||||||
HAp | Lyophilized foam | Mix HAp with doped PPy | N.A./N.A. | ppy: 0.26% w/v | N.A. | Osteoblast/BTR | Higher protein adsorption and drug release rate over a long period in PPy contained composites. | 69 |
PCL | Film | Immerse coating | p-TSA/FeCl3 | [py]: 0.084 M | 1.0 ± 0.4 kΩ cm | HL1/CTE | Higher calcium wave propagation and shorter transient duration on PPy/PCL composites. | 10 |
PCL | Electrospunelectrospray mat | py vapor | p-TSA/FeCl3 | Oxidant electrospraying time: 1–4 h | 1.3–1.9 S/cm | L929/Biocompatibility | PPy/PCL scaffold promoted PC12 attachment or proliferation. | 65 |
PCL | Rolled 3D-printed scaffold | Mix PPy-block-PCL with PCL pellets | N.A./N.A. | [PPy-b-PCL]: 0.5–2%, PCL: 70% | 0.28 ± 0.02–1.15 ± 0.03 mS/cm | hESC-derived NSCs/NTE | PCL/PPy scaffold enhanced cell maturation toward peripheral neuronal cells. | 66 |
PCL/GEL | Electrospun mat | Disperse doped PPy in spinning solution | N.A./N.A. | PPy/PCL-GEL (PPG): 15:85, 30:70 | PPG15: 0.013 mS/cm | Rabbit primary CM/CTE | Higher expression of CX43 in PPy/PCL scaffolds. | 13 |
PPG30: 0.37 mS/cm | ||||||||
PLCL/SF | Electrospun mat | Immerse coating | p-TSA/FeCl3 | [py]: 2 M, volume: 0–50 μL | 8.52 × 10−6–1.36 × 10−4 | In vivo model/NTE | PPy/PLCL/SF mat promoted SCs proliferation in vivo. | 6 |
Thicker myelin in regenerated nerve and better sciatic nerve function recovery. | ||||||||
PCL/PSS | Electrospun mat | Immerse coating | N.A./FeCl3 | [py]: 84 mM | 52.8 ± 4.7 kΩ/sq | hMSCs/BTE | Increased ALP expression and calcium deposition on PPy/PCL/PSS scaffolds both with and without electrical stimulation. | 64 |
PGA | Thermosetting injectable spring | Immerse coating after dopamine treatment | N.A./FeCl3 | [PY]: 0.2 M | 80.84 S/m | HUVECs, RAECs, in vivo model/CTE | Highly oriented sarcomeres. | 94 |
Enhanced CM's maturation in synchronous contraction. | ||||||||
Decreased ventricle infarct size. | ||||||||
PLA | Electrospun mat | Mix synthesized PPy in spinning solution | p123/FeCl3 | [PPy]: 1.8% | N.A. | In vivo model/NTE | PPy/PLA nanofibrous scaffold inhibited scar tissue formation. | 79 |
[PLA]: 12.5% | ||||||||
Induced the axonal regeneration and myelination in the lesion area. | ||||||||
PLA | Electrospun mat | Mix synthesized PPy in spinning solution | p123/FeCl3 | [PPy]: 15% | 1.10 × 10−4 S/cm | In vivo model/NTE | Six weeks after injury, the use of PLA/PPy scaffolds significantly reduced the activation of astrocytes and increased axonal regeneration. | 80 |
PLA/PLO | Electrospun mat | Disperse doped PPy in spinning solution | N.A./N.A. | PPy:PLA (wt/wt): 1–10 | N.A. | PC12/NTE | PPy-containing scaffolds supported PC12 cells differentiation without electrical stimulation, which could be further enhanced with electrical stimulation. | 4 |
PLGA | Micro-grooved scaffold | Immerse coating | NaCl/FeCl3 | [py]: 2.875, 5.75, 11.5 mM | 9.63–38.56 S/cm | mNSCs/NTE | Enhanced mNSCs neuronal differentiation on PPy-coated microgroove scaffolds even without electrical stimulation, which was further enhanced with electrical stimulation. | 77 |
PLGA | Electrospun mat | py vapor, electrochemical polymerization | NaDBS/FeCl3 | [py]: 0.1 M | N.A. | iPSC/CTE | iPSCs on conductive scaffolds showed elevated expression of Actinin, NKX2.5, GATA4, and Myh6 both stimulated and unstimulated. | 67 |
PLGA | Electrospun mat | Immerse coating | pTS/FeCl3 | [py]: 14 mM | 7.4 ± 3.2 × 103–9.0 ± 6.0 × 104 Ω/sq | PC12/NTE | PPy/PLGA meshes supported differentiation of PC12. | 68 |
Longer neurites on conductive scaffold with electrical stimulation than nonstimulated ones. | ||||||||
PGS/COL | Film | Mix PPy with PGS/Col solution | N.A./N.A. | [COL]: 0%, 0.5% | COL 0.5–PPy 5: 0.06 ± 0.14 S/cm | H9C2/CTE and drug release | PPy and collagen improved scaffolds' protein adsorption ability. | 95 |
[PPy]: 0–5% | ||||||||
5% PPy did not change the degradation speed of the patch. | ||||||||
Drug-loaded film promoted cell proliferation till 21 days. |
ALG, alginate; ALP, alkaline phosphatase; APS, ammonium persulfate; BMMSC, bone marrow mesenchymal stem cell; BTE, bone tissue engineering; CHI, chitosan; CM, cardiomyocyte; CMCS, carboxymethyl chitosan; COL, collagen; CTE, cardiac tissue engineering; CX43, Connexin 43; dopa, dopamine; FeCl3, ferric chloride; FepTS, ferric p-toluene sulfonate; GEL, gelatin; HA, hyaluronic acid; HAp, synthetic hydroxyapatite; HCl, hydrochloric acid; hESC, human embryonic stem cell; hMSCs, human mesenchymal stem cells; HUVECs, human umbilical vein endothelial cells; IPC, interfacial polyelectrolyte complexation; iPSCs, induced pluripotent stem cells; mNSCs, mouse neural stem cells; N.A., not applicable; NaDBS, sodium dodecylbenzenesulfonate; NRCM, neonatal rat cardiomyocytes; NTE, neural tissue engineering; p123, poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol); PAR, polyarylate; PCL, polycaprolactone; PGS, poly(glycerol sebacate); PLA, polylactic acid; PLCL, poly(l-lactic acid-co-ɛ-caprolactone); PLGA, poly(lactic-co-glycolic acid); PLO, poly-ornithine; py, pyrrole; PPy, polypyrrole; PSS, polystyrenesulfonate; PT, polythiophene; p-TSA, p-toluene sulfonic acid; PVA, polyvinyl alcohol; RAECs, rat aortic endothelial cells; SA, sodium alginate; SC, Schwann cell; SF, silk fibroin.